Doctors use ejection fraction percentages to categorize left-sided heart failure. According to a 2022 article, people with HFpEF have an ejection fraction of more than 50%.

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

It has specific treatments depending on the type of amyloidosis, in addition to the treatments mentioned above for heart failure. Dear Dr. Roach: I am just getting over the horrible shingles.

US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the orally-administered phosphodiesterase 9 (PDE9) inhibitor, CRD-750, targeting both ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat distribution, with greater weight loss linked to better outcomes, a study ...

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380 (9851):1387-1395. doi ...

Overall, SGLT2 inhibitors show clear benefits in both heart failure with reduced ejection fraction (HFrEF) and HFpEF populations, while sacubitril-valsartan is emerging as an important HFpEF therapy.

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

Solomon, S. D., et al. (2024) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine. doi.org/10.1056/NEJMoa2407107.

Source Reference: Oraii A, et al "Atrial fibrillation ablation in heart failure with reduced vs preserved ejection fraction: a systematic review and meta-analysis" JAMA Cardiol 2024; DOI: 10.1001 ...

Given the current trends, heart failure with normal ejection fraction will become the most common form of heart failure, for which we do not currently have an evidence-based successful treatment.